Synergistic immunosuppressive effects of the mTOR inhibitor sirolimus and the phytochemical curcumin

Phytomedicine

Volumn 20, Issue 2, 2013, Pages 120-123

  Deters, M ^a   Hutten H ^b   Kaever, V ^c  

^a Poisons Information Center (PIC) Erfurt   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antiproliferative; Curcumin; Immunosuppression; PBMC; Sirolimus

Indexed keywords

CURCUMIN; I KAPPA B; INTERLEUKIN 2; OKT 3; RAPAMYCIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IC 50; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

CELL PROLIFERATION; CURCUMA; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; PLANT EXTRACTS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

ANIMALIA; CURCUMA LONGA;

EID: 84871719904     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2012.09.018     Document Type: Article

References (24)

1. B.B. Aggarwal, and K.B. Harikumar Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases International Journal of Biochemistry and Cell Biology 41 2009 40 59
2. D.K. Agrawal, and P.K. Mishra Curcumin and its analogues: potential anticancer agents Medicinal Research Reviews 30 2010 818 860
3. N.P. Barrera, B. Morales, S. Torres, and M. Villalón Principles: mechanisms and modeling of synergism in cellular responses Trends in Pharmacological Sciences 26 2005 526 532
4. M.C. Berenbaum Synergy, additivism and antagonism in immunosuppression. A critical review Clinical and Experimental Immunology 28 1977 1 18
5. R. Busca, C. Bertolotto, J.P. Ortonne, and R. Ballotti Inhibition of the phosphatidylinositol 3-kinase/p70 (S6)-kinase pathway induces B16 melanoma cell differentiation Journal of Biological Chemistry 271 1996 31824 31830
6. M. Deters, H. Knochenwefel, D. Lindhorst, T. Koal, H.H. Meyer, W. Hänsel, K. Resch, and V. Kaever Different curcuminoids inhibit T-lymphocyte proliferation independently of their radical scavenging activities Pharmaceutical Research 25 2008 1822 1827
7. D.A. Dickinson, K.E. Iles, A.F. Wigley, and H.F. Forman Analysis of transcription factor remodeling in phase II gene expression with curcumin Methods in Enzymology 378 2004 302 318
8. J. Epstein, I.R. Sanderson, and T.T. Macdonald Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies British Journal of Nutrition 103 2010 1545 1557
9. B. Geoerger, K. Kerr, C.B. Tang, K.M. Fung, B. Powell, L.N. Sutton, P.C. Phillips, and A.J. Janss Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy Cancer Research 61 2001 1527 1532
10. W.R. Greco, G. Bravo, and J.C. Parsons The search for synergy: a critical review from a response surface perspective Pharmacological Reviews 47 1995 331 385
11. M. Grewe, F. Gansauge, R.M. Schmid, G. Adler, and T. Seufferlein Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells Cancer Research 59 1999 3581 3587
12. H. Hosoi, M.B. Dilling, T. Shikata, L.N. Liu, L. Shu, R.A. Ashmun, G.S. Germain, R.T. Abraham, and P.J. Houghton Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells Cancer Research 59 1999 886 894
13. B.D. Kahan Ten years of mTOR inhibitor therapy Transplantation Proceedings 35 2003 3S 24S
14. S. Muthukkumar, T.M. Ramesh, and S. Bondada Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells Transplantation 60 1995 264 270
15. T. Ogawa, M. Tokuda, K. Tomizawa, H. Matsui, T. Itano, R. Konishi, S. Nagahata, and O. Hatase Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells Biochemical and Biophysical Research Communications 249 1998 226 230
16. H. Pang, and L.E. Faber Estrogen and rapamycin effects on cell cycle progression in T47D breast cancer cells Breast Cancer Research and Treatment 70 2001 21 26
17. L. Pari, D. Tewas, and J. Eckel Role of curcumin in health and disease Archives of Physiology and Biochemistry 114 2008 127 149
18. D. Ranjan, T.D. Johnston, G. Wu, L. Elliot, S. Bondada, and M. Nagabhushan Curcumin blocks cyclosporine A-resistant CD28 costimulatory pathway of human T-cell proliferation Journal of Surgical Research 77 1998 174 178
19. S.N. Sehgal Rapamune (sirolimus, rapamycin): an overview and mechanism of action Therapeutic Drug Monitoring 17 1995 660 665
20. T. Seufferlein, and E. Rozengurt Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells Cancer Research 56 1996 3895 3897
21. H.G. van der Poel, C. Hanrahan, H. Zhong, and J.W. Simons Rapamycin induces Smad activity in prostate cancer cell lines Urological Research 30 2003 380 386
22. B. Vieregge, K. Resch, and V. Kaever Synergistic effects of the alkaloid sinomenine in combination with the immunosuppressive drugs tacrolimus and mycophenolic acid Planta Medica 65 1999 80 82
23. H. Zhou, C.S. Beevers, and S. Huang The targets of curcumin Current Drug Targets 12 2011 332 347
24. H. Zhou, Y. Luo, and S. Huang Updates of mTOR inhibitors Anti-cancer Agents in Medicinal Chemistry 10 2010 571 581